At the forefront of the SBF 120, bioMérieux stock climbs 2%
The in vitro diagnostics manufacturer enjoys a well-oriented session, while the Paris exchange loses ground. After a rebound underway for several weeks, the stock is now eyeing a technical threshold nearby.
The stock exceeds its short-term averages and targets a resistance level nearby
The bioMérieux stock gains 2.21% to €78.45 in early afternoon, among the strongest increases in the SBF 120, while the index declines by 0.46%. The price is above the 20-day moving average (€74.18) with a gap of 5.76% and above the 50-day moving average (€73.69) with a gap of 6.46%, but remains 5.70% below the 200-day moving average (€83.19). The stock is thus approaching its resistance at €79.70, a level 1.6% away from the current price, while the RSI at 56 remains neutral. Over three months, the value advances 12.55%, which contrasts with a decline of 32.72% over one year.
A confirmed GO•28 plan and a Spinchip test launched at the end of September
During the publication of the first half of 2026, on August 4, the group confirmed its outlook for the year: organic revenue growth of 3% to 5% and current operating income growth of 0% to 10%. Among the risks cited on this occasion was weaker respiratory epidemiology, with an organic decline of 17% in BIOFIRE respiratory panels. On the product side, bioMérieux launched on September 24 Spinchip, a troponin test in 10 minutes for emergency care, as part of the GO•28 plan.
The stock had then broken through its resistance at €75.80. The next technical target is now located at €79.70.
